FTY720: A new kid on the block for transplant immunosuppression

Expert Opinion on Biological Therapy

Volumn 3, Issue 4, 2003, Pages 665-681

  Aki, Fazil Tuncay ^a   Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cyclosporin; FTY720; Immunosuppression; Sirolimus; Tacrolimus

Indexed keywords

BINDING PROTEIN; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; FINGOLIMOD; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; STEROID; TACROLIMUS;

ADRENAL CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRADYCARDIA; BRONCHOSPASM; CELL ADHESION; CELL PROLIFERATION; CHRONOTROPISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYTOKINE PRODUCTION; DIABETES MELLITUS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DYSPNEA; ENDOTHELIUM CELL; FETOTOXICITY; FUNGUS CULTURE; FUTUROLOGY; GRAFT SURVIVAL; HERPES ZOSTER; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; ISARIA SINCLAIRII; LIVER TOXICITY; LYMPHOCYTE MIGRATION; LYMPHOCYTOPENIA; MOUSE; MUSCLE HYPERTROPHY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PANCREAS DISEASE; PERIPHERAL NERVE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RAT; REVIEW; SIDE EFFECT; SIGNAL DETECTION; STOMACH ULCER; STRUCTURE ANALYSIS; TRANSPLANTATION; URINARY TRACT INFECTION;

ANIMALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DOGS; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; MICE; PRIMATES; PROPYLENE GLYCOLS; RATS; REPERFUSION INJURY; SPHINGOSINE; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; FUNGI; ISARIA; PRIMATES; RODENTIA;

EID: 0037926871     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.4.665     Document Type: Review

References (110)

1. HARIHARAN S, JOHNSON CP, BRESNAHAN BA et al.: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N. Engl. J. Med. (2000) 342:605-612. This retrospective analysis of the influence of demographic characteristics and transplant and post-transplant variables on graft survival for 93,934 renal transplantations performed in the US between 1988 and 1996 concludes that there has been a substantial increase in short-term and long-term survival of kidney grafts from both living and cadaveric donors.
2. TIMONEN P, FRIEND D, ABEYWICKRAMA K et al.: Efficacy of low-dose cyclosporin A in psoriasis: results of dose-finding studies. Br. J. Dermatol. (1990) 122:33-39.
3. FEUTREN G, MIHATSCH MJ: Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N. Engl. J. Med. (1992) 326:1654-1660.
4. HALLORAN P, MATHEW T, TOMLANOVICH S et al.: Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in the prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation (1997) 63:39-47.
5. KAHAN BD: Sirolimus: a comprehensive review. Expert Opin. Pharmacother. (2001) 2:1903-1917.
6. GROTH CG, BACKMAN L, MORALES JM et al.: Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation (1999) 67:1036-1042.
7. KREIS H, CISTERNE JM, LAND W et al.: Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation (2000) 69:1252-1260.
8. KAHAN BD: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet (2000) 356:194-202.
9. MACDONALD AS: A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. The Rapamune US Study Group. Transplantaion (2001) 71:271-280.
10. KAHAN BD, KRAMER WG: Median effect analysis of efficacy versus adverse effects of immunosuppressants. Clin. Pharmacol. Ther. (2001) 70:74-81.
11. FUJITA T, INOUE K, YAMAMOTO S et al.: Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J. Antibiotics (1994) 47:208-215.
12. FUJITA T, YONETA M, HIROSER et al.: Simple compounds, 2-alkyl-2-amino-1,3-propanediols have potent immunosuppressive activity. Bio. Med. Chem. Lett. (1994) 5:847-852.
13. ADACHI K, KAHORA T, NAKAO N et al.: Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: discovery of a novel immunosuppressant, FTY720. Bio. Med. Chem. Lett. (1995) 5:853-856. The study reported that FTY720 obtained by modification of ISP-1 (myriocin) displayed potent immunosuppressive activity both in vivo and in vitro in a dose-dependent manner, without toxic side effects.
14. MANDALA S, HAJDU R, BERGSTROM J et al.: Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science (2002) 296:346-349. This study showed that lymphocyte trafficking is altered by the lysophospholipid S1P and by a phosphoryl metabolite of the immunosuppressive agent FTY720, producing lymphopenia in blood and thoracic duct lymph by sequestration of lymphocytes in lymph nodes, but not spleen. Inhibition of lymphocyte recirculation by activation of S1P receptors may result in therapeutically useful immunosuppression.
15. BRINKMANN V, DAVIS MD, HEISE CE et al.: The immune modulator, FTY720, targets sphingosine-1-phosphate receptors. J. Biol. Chem. (2002) 277:21453-21457. The results of this study utilising an experimental rodent model of autoimmune encephalomyelitis suggest that after phosphorylation, FTY720 acts through S1P signalling pathways to modulate chemotactic responses and lymphocyte trafficking.
16. CHIBA K, HOSHINO Y, SUZUKI C et al.: FTY720, A novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant. Proc. (1996) 28:1056-1059.
17. WANG ME, TEJPAL N, QU X et al.: Immunosuppressive effects of FTY720 alone or in combination with cyclosporine or sirolimus. Transplantation (1998) 65:899-905. The study examined the ability of FTY720 to prolong buffalo heart allograft survival in Wistar-Furth rats and to potentiate the immunosuppressive effects of CsA and/or sirolimus.
18. CHIBA K, YANAGAWA Y, MASUBUCHI Y et al.: FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. (1998) 160:5037-5044. The study found that FTY720 significantly prolonged skin allograft survival in a dose-dependent manner, displaying more potent immunosuppressive activity than CsA or tacrolimus in MHC-incompatible rat strains. The authors suggest that the mechanism of action of FTY720 is sequestration of circulating mature lymphocytes into PLN, MLN, and Peyer's patches.
19. MIYAKE Y, KOZUTSUMI Y, NAKAMURA S, FUJITA T, KAWASAKI T: Serine palmitoyltranferase is the primary target of a sphingosine-like immunosuppressant, ISP-I/Myriocin. Biochem. Biophys. Res. Comm. (1995) 211:396-403.
20. SUZUKI S, ENOSAWA S, KAKEFUDA T et al.: A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation (1996) 61:200-205. Rat spleen cells incubated with FTY720 demonstrated features characteristic of apoptosis by electron microscopy and genomic DNA fragmentation upon agarose gel electrophoresis. The drug prolonged rat liver allograft survivals to 50 days in 10 recipients, an effect that was potentiated in combination with CsA when it was delivered to recipients of canine kidney allografts.
21. BÖHLER T, WAISER J, SCHÛTZ M et al.: FTY720A mediates reduction of lymphocyte counts in human renal allograft recipients by an apoptosis-independent mechanism. Transpl. Int. (2000) 13:S311-S313.
22. BUDDE K, SCHMOUDER RL, BRUNKHORST R et al.: First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. (2002) 13:1073-1083. This Phase I, single-dose, multi-centre clinical trial that utilised a randomised, double-blind, placebo-controlled design in stable renal transplant patients treated with CsA-based immunosuppression showed that FTY720 was well-tolerated with no serious adverse events.
23. KAHAN B, CHODOFF L, LEICHTMAN A et al.: Safety and pharmacodynamics of multiple doses of FTY720 in stable renal transplant recipients [Abstract 654]. Am. J. Transplant. (2001) 1:300.
24. PINSCHEWER DD, OCHSENBEIN AF, ODERMATT B et al.: FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol (2000) 164:5761-5770. FTY720 treatment (T cell responses) of mice infected with either LCMV or vesicular stomatitis virus (B cell antibody responses) caused a reversible shift in circulating T cell lymphocytes from the spleen to PLN with markedly reduced delayed-type hypersensitivity reactions to a viral MHC class I-presented peptide. FTY720 also delayed or prevented disease in a CD8+ T cell-mediated diabetes model of a transgenic mouse expressing LCMV glycoprotein.
25. CHIBA K, YANAGAWA Y, KATAOKA H et al.: FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing. Transplant. Proc. (1999) 31:1230-1233.
26. YANAGAWA Y, SUGAHARA K, KATAOKA H et al.: FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats: II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J. Immunol. (1998) 160:5493-5499. FTY720 (0.1 mg/kg) combined with CsA (10 mg/kg) synergistically prolonged Wistar King Aptekman Hokkaido skin allograft survival in MHC-incompatible F344 rats, confirming prolonged survival times and potentiation of the effects of CsA. Semiquantitative polymerase chain reaction analysis, immunohistochemical staining and flow cytometry compared the activities of cell populations in animals treated with FTY720 alone or in combination with CsA.
27. SHIMIZU C, LI X, KIMURA M et al.: A novel immunosuppressant, FTY720, increases the efficiency of a superantigen-induced peripheral T-cell deletion whilst inhibiting negative selection in the thymus. Immunology (1998) 94:503-512.
28. SUZUKI S, LI XK, SHINOMIYA T et al.: The in vivo induction of lymphocyte apoptosis in MRL-lpr/lpr mice treated with FTY720. Clin. Exp. Immunol. (1997) 107:103-111.
29. SUZUKI S, LI XK, ENOSAWA S, SHINOMIYA T: A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes. Immunology (1996) 89:518-523.
30. LI XK, SHINOMIYA T, ENOSAWA S et al.: Induction of lymphocyte apoptosis by a novel immunosuppressant FTY720: relation with FAS, Bcl-2 and Bax expression. Transplant. Proc. (1997) 29:1267-1268.
31. FUJINO M, LI XK, GUO L et al.: T-cell apoptosis triggered by FTY720 via mitochondrial pathway. Transplant. Proc. (2001) 33:3084-3085.
32. NAGAHARA Y, IKEKITA M, SHINOMIYA T: Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria. J. Immunol. (2000) 165:3250-3259.
33. OHTA H, SWEENEY EA, MASAMUNE A et al.: Induction of apoptosis by sphingosine in human leukemic HL-60 cells: a possible endogenous modulator of apoptotic DNA fragmentation occurring during phorbol ester-induced differentiation. Cancer Res. (1995) 55:691-697.
34. SHINOMIYA T, LI XK, AMEMIYA H, SUZUKI S: An immunosuppressive agent, FTY720, increases intracellular concentration of calcium ion and induces apoptosis of HL-60. Immunology (1997) 91:594-600.
35. MATSUDA T, NAKAJIMA H, FUJIWARA I, MIZUTA N, OKA T: Caspase requirement for the apoptotic death of WR19L-induced by FTY720. Transplant. Proc. (1998) 30:2355-2357.
36. MATSUDA S, MINOWA A, SUZUKI S, KOYASU S: Differential activation of c-jun NH2-terminal kinase and p38 pathways during FTY720-induced apoptosis of T lymphocytes that is suppressed by the extracellular signal-regulated kinase pathway. J. Immunol. (1999) 162:3321-3326.
37. BRINKMANN V, WILT C, KRISTOFIC K et al.: Dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent anti-proliferative and apoptotic effects. Transplant. Proc. (2001) 33:3078-3080.
38. BRINKMANN V, LYNCH KR: FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr. Opin. Immunol. (2002) 14:569-575.
39. YANAGAWA Y, HOSHINO Y, KATAOKA H et al.: FTY720, a novel immunosuppressant, prolongs rat skin allograft survival by decreasing T-cell infiltration into grafts. Transplant. Proc. (1999) 31:1227-1229.
40. LI XK, ENOSAWA S, KAKEFUDA T, AMEMIYA H, SUZUKI S: FTY720, a novel immunosuppressive agent, enhances upregulation of the cell adhesion molecular ICAM-1 in TNF-alpha treated human umbilical vein endothelial cells. Transplant. Proc. (1997) 29:1265-1266.
41. YANAGAWA Y, MASUBUCHI Y, CHIBA K: FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing. Immunology (1998) 95:591-594.
42. BAI Y, LIU J, WANG Y et al.: L-selectin-dependent lymphoid occupancy is required to induce alloantigen-specific tolerance. J. Immunol. (2002) 168:1579-1589.
43. SPRINGER TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell (1994) 76:301-314.
44. KAHAN BD: FTY720: a new dimension in transplantation. Transplant. Proc. (2001) 33:3081-3083.
45. LUTHER SA, BIDGOL A, HARGREAVES DC et al.: Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J. Immunol (2002) 169:424-433.
46. HENNING G, OHL L, JUNT T et al.: CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720. J. Exp. Med. (2001) 194:1875-1881. FTY720 exerted its homing actions to some extent in both CCR7 (-/-) and plt (-/-) mice, suggesting the presence of an alternative mechanism to the G-alpha(i)-dependent interaction of CCR7 with CCL19/CCL21.
47. NAGIRA M, IMAI T, HIESHIMA K et al.: Molecular cloning of a novel human CC chemokine secondary lymphoid-tissue chemokine that is a potent chemoattractant for lymphocytes and mapped to chromosome 9p13. J. Biol. Chem. (1997) 272:19518-19524.
48. GUNN MD, KYUWA S, TAM C et al.: Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J. Exp. Med. (1999) 189:451-460.
49. LUTHER SA, TANG HL, HYMAN PL, FARR AG, CYSTER JG: Coexpression of the chemokines ELC and SLC by T zone stromal cells and deletion of the ELC gene in the plt/plt mouse. Proc. Natl. Acad. Sci. USA (2000) 97:12694-12699.
50. NAKANO H, MORI S, YONEKAWA H et al.: A novel mutant gene involved in T-lymphocyte-specific homing into peripheral lymphoid organs on mouse chromosome 4. Blood (1998) 91:2886-2895.
51. HLA T, LEE MJ, ANCELLIN N, PAIK JH, KLUK MJ: Lysophospholipids-receptor revelations. Science (2001) 294:1875-1878.
52. HLA T: Sphingosine 1-phosphate receptors. Prostaglandins Other Lipid Mediat. (2001) 64:135-142.
53. IDZKO M, PANTHER E, CORINTI S et al.: Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses. FASEB J. (2002) 16:625-627.
54. CHEN S, BACON KB, GARCIA G et al.: FTY720, a novel transplantation drug, modulates lymphocyte migratory responses to chemokines. Transplant. Proc. (2001) 33:3057-3063. This study demonstrated for the first time that FTY720 increases the intrinsic motility and chemotactic responses of lymphocytes.
55. GRAELER M, SHANKAR G, GOETZL EJ: Cutting edge: suppression of T cell chemotaxis by sphingosine 1-phosphate. J. Immunol. (2002) 169:4084-4087.
56. LUO ZJ, TANAKA T, KIMURA F, MIYASAKA M.: Analysis of the mode of action of a novel immunosuppressant FTY720 in mice. Immunopharmacology (1999) 41:199-207.
57. NAGAHARA Y, EOSAWA S, IKEKITA M, SUZUKI S, SHINOMIYA T: Evidence that FTY720 induces T cell apoptosis in vivo. Immunopharmacology (2000) 48:75-85.
58. XU M, PIRENNE J, ANTONIOU S et al.: FTY720 compates with FK 506 as rescue therapy in rat heterotopic cardiac transplantation. Transplant. Proc. (1998) 30:2221-2222.
59. XU M, PIRENNE J, ANTONIOU EA et al.: Effect of peritransplant FTY720 alone or in combination with post-transplant tacrolimus in a rat model of cardiac allotransplantation. Transpl. Int. (1998) 11:288-294.
60. KUNIKATA S, NAGANO T, NISHIOKA T, AKIYAMA T, KURITA T: Immunosuppressive action of FTY720 for renal allograft a rat model. Transplant. Proc. (1999) 31:1157-1159.
61. STEPKOWSKI SM, WANG M, QU X et al.: Synergistic interaction of FTY720 with cyclosporine of sirolimus to prolong heart allograft survival. Transplant. Proc. (1998) 30:2214-2216.
62. FANG Y, VILELLA-BACH M, BACHMANN R, FLANIGAN A, CHEN J: Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science (2001) 294:1942-1945.
63. HOSHINO Y, YANAGAWA Y, OHTSUKI M et al.: FTY720, a novel immunosuppressant, shows a synergistic effect in combination with FK 506 in rat allograft models. Transplant. Proc. (1999) 31:1224-1226.
64. NIKOLOVA Z, HOF A, BAUMLIN Y, HOF RP: The peripheral lymphocyte count predicts graft survival in DA to Lewis heterotopic heart transplantation treated with FTY720 and SDZ RAD. Transpl. Immunol. (2000) 8:115-124.
65. OHBA M, LI XK, KITA Y et al.: Long-term graft acceptance in rat heart transplantation by CTLA4Ig gene transfection combined with FTY720 treatment. World J. Surg. (2001) 25:391-397.
66. KITA Y, LI XK, FUNESHIMA N et al.: Prolonged graft survival induced by CTLA4IG-gene transfection combined with FTY720 administration in rat heart grafting. Transplant. Proc. (1999) 31:2787-2788.
67. TRONCOSO P, STEPKOWSKI SM, WANG ME et al.: Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine. Transplantation (1999) 67:145-151. Cynomolgus monkeys bearing incompatible kidney allografts and treated with daily intramuscular injections of subtherapeutic doses of CsA alone or in combination with intravenous bolus injections of FTY720 at three dose levels (0.1, 0.3 or 1.0 ng/ml) showed a beneficial effect of the addition of FTY720.
68. QUESNIAUX V, MENNINGER K, AUDET M, GASCHEN L, SCHUURMAN HJ: FTY-720 is efficacious in monkey kidney transplantation. Transplant. Proc. (2001) 33:2374-2375.
69. HWANG MW, MATSUMORI A, FURUKAWA Y et al.: FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Circulation (1999) 100:1322-1329.
70. KOSHIBA T, DAMME BV, LU Y et al.: Combined use of FTY720 and cyclosporine A prevents chronic allograft vasculopathy. Transplant. Proc. (2002) 34:748-749.
71. CHUEH S, CHEN J, CHEN J, LAI M: FTY720 prevents chronic rejection of rat heterotopic cardiac allografts, Transplant. Proc. (2001) 33:542-543.
72. NIKOLOVA Z, HOF A, RUDIN M et al.: Prevention of graft vessel disease by combined FTY720/cyclosporine. A treatment in a rat carotid artery transplantation model. Transplantation (2000) 69:2525-2530. The combination of FTY720 and clinically relevant exposures to cyclosporine completely suppressed the development of graft vessel disease in a Lewis rat carotid artery allograft model.
73. NIKOLOVA Z, HOF RP: Neointima suppression in rat carotid allografts by FTY720 combined with a small fixed cyclosporine dose is related to a diminution of the peripheral lymphocyte count. Transplant. Proc. (2001) 33:2184-2185.
74. NIKOLOVA Z, HOF A, BAUMLIN Y, HOF RP: Efficacy of SDZ RAD compared with CsA monotherapy and combined Rad/FTY720 treatment in a murine cardiac allotransplantation model. Transpl. Immunol. (2001) 9:43-49.
75. CHUEH SC, TIAN L, WANG M et al.: Induction of tolerance toward rat cardiac allografts by treatment with allochimeric class I MHC antigen and FTY720. Transplantation (1997) 64:1407-1414.
76. MIYATA Y, OHDAN H, NORIYUKI T et al.: Prolongation of concordant xenograft survival by treatment with FTY720. Transplant. Proc. (1998) 30:4163-4165.
77. FUKUDA Y, OHDAN H, MIYATA Y, SHINTAKU S, DOHI K: Effect of FTY720 on immunoregulation in concordant xenotransplantation. Transpl. Int. (1998) 11:S461-S464.
78. FU F, HU S, LI S et al.: FTY720, a novel immunosuppressive agent with insulinotropic activity, prolongs graft survival in a mouse islet transplantation model. Transplant. Proc. (2001) 33:672-673.
79. ZHANG J, SONG Z, WIJKSTROM M et al.: FTY720 in combination with CsA inhibits islet xenograft rejection: a study in the pig-to-rat model. Transplant. Proc. (2000) 32:1017.
80. TRONCOSO P, ORTIZ M, MARTINEZ I, KAHAN BD: FTY720 prevents ischemic reperfusion damage in rat kidneys. Transplant. Proc. (2001) 33:857-859. FTY720 (1.0 mg/kg) displayed a moderate protective effect on renal function when administered immediately after in situ warm ischaemia in rats.
81. DRAGUN D, WAISER J, BOHLER T et al.: Pretreatment with FTY720 protects renal allografts against preservation-reperfusion injury [Abstract 62]. XVIII International Congress of the Transplantation Society (2000):S127.
82. TAKAHARA S, TANAKA T, WANG JD et al.: FTY720 prevents ischemic/reperfusion injury in murine kidney [Abstract 400]. Am. J. Transplant. (2001) 1:255.
83. ANSELMO DM, AMERSI FF, SHEN XD et al.: FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration. Am. J. Transplant. (2002) 2:843-849.
84. MIZUTA K, OHMORI M, MIYASHITA F et al.: Effect of pretreatment with FTY720 and cyclosporin on ischaemia-reperfusion injury of the liver in rats. J. Pharm. Pharmacol. (1999) 51:1423-1428.
85. MATSUURA M, IMAYOSHI T, CHIBA K, OKUMOTO T: Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats. Inflamm. Res. (2000) 49:404-410.
86. MATSUURA M, IMAYOSHI T, OKUMOTO T: Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats. Int. J. Immunopharmacol. (2000) 22:323-331.
87. KUROSE S, IKEDA E, TOKIWA M, HIKITA N, MOCHIZUKI M: Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats. Exp. Eye Res. (2000) 70:7-15.
88. HOZUMI Y, KOBAYASHI E, MIYATA M, FUJIMURA A: Immunotherapy for experimental rat autoimmune thyroiditis using a novel immunosuppressant, FTY720. Life Sci. (1999) 65:1739-1745.
89. KITABAYASHI H, ISOBE M, WATANABE N et al.: FTY720 prevents development of experimental autoimmune myocardids through reduction of circulating lymphocytes. J. Cardiovasc. Pharmacol. (2000) 35:410-416.
90. MIYAMOTO T, MATSUMORI A, HWANG MW et al.: Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis. J. Am. Coll. Cardiol. (2001) 37:1713-1718.
91. OKAZAKI H, HIRATA D, KAMIMURA T et al.: Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J. Rheumatol. (2002) 29:707-716.
92. FU F, HU S, DELEO J et al.: Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. Transplantation (2002) 73:1425-1430.
93. BRINKMANN V, CHEN S, FENG L et al.: FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transplant. Proc. (2001) 33:530-531.
94. TEDESCO H, KAHAN BD, MOURAD G et al.: FTY720 combined with Neoral and corticosteroids is effective and safe in prevention of acute rejection in renal allograft recipients (interim data) [Abstract 429]. Am. J. Transplant. (2001) 1:243.
95. FERGUSON RM, MULGAONKAR S, TEDESCO H et al.: FTY720 with reduced-exposure Neoral provides adequate rejection prophylaxis in de novo renal transplant recipients [Abstract 49]. Transplantation (2002) 74:34.
96. SKERJANEC A, HSU C, PELLET P et al.: Systemic exposure and preliminary efficacy of FTY720 in de novo renal transplant recipients [Abstract 964]. Am. J. Transplant. (2002) 2:380.
97. LORBER M, TEDESCO-SILVA H, FELIPE CR et al.: FTY720, RAD and corticosteroids for the prevention of graft loss and acute rejection in renal allograft recipients at increased risk of delayed graft function [Abstract 962]. Am. J. Transplant. (2002) 2:380.
98. TEDESCO-SILVA H, ROSSO-FELIPE C, LORBER M et al.: FTY720, RAD and corticosteroids for the prevention of graft loss and acute rejection in renal allograft recipients at increased risk of delayed graft function [Abstract 50]. Transplantation (2002) 74:34.
99. KAHAN BD: FTY720 in combination with everolimus: a novel CNI-free regimen as effective in Afro-Americans as in Caucasians at high risk for DGF [Abstract]. Am. J. Transplant. (2003) (In Press).
100. KAHAN BD: FTY720: a new immunosuppressive agent with novel mechanism(s) of action. Transplant. Proc. (1998) 30:2210-2213.
101. LILIOM K, SUN G, BUNEMANN M et al.: Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. Biochem. J. (2001) 355:189-197.
102. GUO J, MACDONELL KL, GILES WR: Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells. Pflugers Arch. (1999) 438:642-648.
103. MAZURAIS D, ROBERT P, GOUT B et al.: Cell type-specific localization of human cardiac S1P receptors. J. Histochem. Cytochem. (2002) 50:661-670.
104. SCHMOUDER R, DANNECKER R, CHOUDHURY S, BARILLA D, SABLINSKI T: FTY720 metabolism in humans [Abstract 1338]. Am. J. Transplant (2001) 1:475.
105. ZIMMERLIN AG, PATTEN CJ: Role of CYP4F in the metabolic clearance of FTY720: prediction of low drug to drug interaction potential [Abstract 300]. Transplantation (2000) 69:S191.
106. BARILLA D, CHOUDHURY S, LEDFORD P, FIGUEIREDO J, SCHMOUDER R: Effect of impaired hepatic function on the systemic exposure of FTY720 [Abstract 1342]. Am. J. Transplant. (2001) 1:476.
107. CHOUDHURY S, KAHAN BD, LEICHTMAN AB: Absorption and disposition of multiple dose FTY720 in humans [Abstract 1831. Transplantation (2000) 69:S160.
108. TAMURA A, LI XK, FUNESHIMA N et al.: Immunosuppressive therapy using FTY720 combined with tacrolimus in rat liver transplantation. Surgery (2000) 127:47-54.
109. SUZUKI K, KAZUI T, KAWABE A et al.: Immunosuppressive effect of FTY720 on rat pancreas allograft. Transplant. Proc. (1998) 30:3417-3418.
110. FURUKAWA H, SUZUKI T, JIN MB et al.: Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720: effect of monotherapy and combined treatment with conventional drugs. Transplantation (2000) 69:235-241.